Polycystic Ovary Syndrome (PCOS), a common hormonal disorder affecting approximately 170 million women globally, has been renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS) during the European Congress of Endocrinology in Prague. This change follows a 14-year international effort to better reflect the disorder's complexity. The term 'polycystic' was deemed misleading, as many women diagnosed with PCOS do not have ovarian cysts. The new name emphasizes that PMOS affects multiple hormone systems and metabolic health, not just reproductive functions. Although the diagnostic criteria remain unchanged, experts hope this rebranding will encourage healthcare providers to adopt a more holistic treatment approach that addresses metabolic and mental health issues. The transition to PMOS will take time, with a global education campaign planned to raise awareness among healthcare professionals and patients, aiming for full adoption by the 2028 International Guideline update.